Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR-AML: CD371-YSNVZ-IL18 CAR T cells in Relapsed/Refractory Acute Myeloid Leukemia
NCT06017258Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2023
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD371-YSNVZ-IL18 CAR T cells in acute myeloid leukemia (AML) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 6 months. Started Sep 2023; status: recruiting.
02
Drugs
CD371-YSNVZ-IL18 CAR T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06017258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06017258.